当前位置：
X-MOL 学术
›
Nat. Rev. Urol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Overall survival with adjuvant pembrolizumab in renal cell carcinoma — the shock of the lightning
Nature Reviews Urology ( IF 12.1 ) Pub Date : 2024-05-17 , DOI: 10.1038/s41585-024-00896-6 Francesco Massari 1, 2 , Matteo Rosellini 1, 2 , Veronica Mollica 1
Nature Reviews Urology ( IF 12.1 ) Pub Date : 2024-05-17 , DOI: 10.1038/s41585-024-00896-6 Francesco Massari 1, 2 , Matteo Rosellini 1, 2 , Veronica Mollica 1
Affiliation
|
In the KEYNOTE-564 trial, patients with resected clear cell renal cell carcinoma at a high risk of relapse experienced disease-free survival and especially overall survival benefits following treatment with pembrolizumab, which in turn was established as the novel standard adjuvant therapy for these patients. Accurate patient selection is crucial. Managing post-pembrolizumab recurrence is challenging owing to limited evidence for guiding therapeutic decisions based on clinical features.
中文翻译：
肾细胞癌辅助帕博利珠单抗的总生存期——闪电的冲击
在 KEYNOTE-564 试验中，患有高复发风险的切除透明细胞肾细胞癌的患者在接受派姆单抗治疗后经历了无病生存，尤其是总体生存获益，而派姆单抗又被确立为这些患者的新型标准辅助治疗。准确的患者选择至关重要。由于根据临床特征指导治疗决策的证据有限，管理派姆单抗后复发具有挑战性。
更新日期：2024-05-17
中文翻译：
肾细胞癌辅助帕博利珠单抗的总生存期——闪电的冲击
在 KEYNOTE-564 试验中，患有高复发风险的切除透明细胞肾细胞癌的患者在接受派姆单抗治疗后经历了无病生存，尤其是总体生存获益，而派姆单抗又被确立为这些患者的新型标准辅助治疗。准确的患者选择至关重要。由于根据临床特征指导治疗决策的证据有限，管理派姆单抗后复发具有挑战性。
京公网安备 11010802027423号